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Abstract 
We show that the antibacterial gent, (6S)-6-fluoroshikimate, is a substrate for the shikimate transport system of Escherichia coli 
because in exchange-diffusion experiments it displaced intracellular [~4C]shikimate with the same kinetics as did unlabelled shikimate. 
Other shikimate analogues were also substrates: asjudged by similar experiments or, in the case of (6R)-6-fluoroshikimate, by inference. 
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(6S)-6-Fluoroshikimate inhibits the growth of Es- 
cherichia coli on a glucose-ammonium-salts medium: most 
likely by being converted to fluorochorismate and subse- 
quently inhibiting the synthesis of p-aminobenzoate [1,2]. 
However, spontaneous resistant variants occur at high 
frequency, which is predicted to limit the usefulness of the 
compound for antibacterial chemotherapy in human 
medicine [3]. Such resistant variants cannot take up 
[~4C]shikimate whereas wild-type strains can; and in E. 
coli K-12, the resistance mapped at or near shiA [3], one 
of at least two loci that determine the shikimic acid uptake 
phenotype [4,5]. 
The specificity of the shikimic acid transport system is 
unexplored: but because of the above observations we 
predicted that (6S)-6-fluoroshikimate should be a sub- 
strate. Here we describe the results of testing this hypothe- 
sis, using an exchange-diffusion method evised by Brown 
and Doy [5]. We explored the specificity of the shikimate 
transport system of E. coli further by performing similar 
experiments with other shikimate analogues. 
Fig. 1 shows the structures of shikimic acid and its 
analogues used in the present work. The analogues II, III 
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and IV were prepared substantially pure at ZENECA Phar- 
maceuticals. Compounds V, VI and VII were provided by 
E. Haslam (Sheffield University) as an unresolved mixture 
in molar proportion 68:24:8, respectively. Shikimic acid, 
barium chorismate, amino acids, and N-2-hydroxyethyl- 
piperazine-N'-2-ethanesulfonic ac d (Hepes) were from 
Sigma, Dorset, UK. [14C]Shikimic acid (21.9 mCi/mmol; 
100 /zCi/ml) was from New England Nuclear. Other 
reagents were obtained from commercial sources at analyt- 
ical grade. 
For transport experiments, bacteria were grown in liq- 
uid, or on agar-solidified, Medium 56 [6] containing lu- 
cose (0.2%, w/v), and the following supplements: shikimic 
acid (10 /zg/ml), thiamine (3.4 /zg/ml), and proline, 
arginine and histidine (25 /zg of each/ml) .  E. coli strain 
AB1360 [his4 proA argE aroD xyl thi lac gal mtl tsx (A)- 
F-] was obtained from A.J. Pittard (University of Mel- 
bourne, Parkville, Victoria, Australia). Strain AB1360-7 
was selected by us as a spontaneous variant that would 
take up shikimic acid more rapidly than the parent strain, 
AB 1360 [3]. The selection was carried out as described by 
Brown and Doy [5], by picking rapidly-growing variants 
from agar plates of Medium 56 agar [6] containing shikimic 
acid (100 /xg/ml) as the sole source of aromatic om- 
pounds. The identity of the variant was confirmed by its 
possession of the following auxotrophic markers of the 
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Fig. 1. The structures of shikimic acid and its analogues studied in the 
present work. I, Shikimic acid; II, (6S)-6-fluoroshikimic acid; III, (6R)- 
6-fluoroshikimic a id; IV, (6R)-6-fluoro-4-epihydroxyshikimic acid; V, 
2-methylshikimic acid; VI, 1,2-fl-methyleneshikimic acid; VII, 1,2-ct- 
methyleneshikimic acid. 
parent strain: his, pro,  arg, aro and thi. Susceptibility- 
testing was performed using E. coi l  K-12 NCTC 10538 as 
described previously [3]: using 2-ml portions of solidified 
Davis and Mingioli glucose-salts medium supplemented 
with thiamine. 
In order to demonstrate exchange-diffusion, weadopted 
the conditions used by Brown and Doy [5]; that is: low 
density of cells and large sample volume; and a low initial 
concentration of the reporter substrate, [14C]shikimate, fol- 
lowed by a thousand-fold excess of the non-radiolabelled 
test substrate. We chose not simply to measure inhibition 
of the uptake of [14C]shikimate because this would not 
have differentiated between competitive binding of a test 
substrate without its transport, and competitive transport 
per se. 
A starter culture was grown without shaking in 50 ml of 
Medium 56 in a 100-ml conical flask at 37°C for 16 h, to 
an OD550 of about 0.85 (here and below, optical densities 
refer to a path length of 1 cm). Two further 50-ml volumes 
of the same medium were inoculated with 0.5 ml each of 
the starter culture. These were incubated without shaking 
at 37°C for 8-10 h, whereupon the OD550 was 0.30-0.33. 
The suspensions were combined and the cells harvested by 
centrifugation at 7800 × g for 10 min at 30°C (Sorvall 
RC5C; SS-34 rotor: Ray 7 cm) and washed twice by 
resuspension, in fresh Medium 56 containing lucose but 
none of the auxotrophy supplements, and recentrifugation 
as above. The final pellet was resuspended in 10 ml of 
Medium 56 containing glucose and the proline, histidine 
and thiamine supplements. Arginine was omitted in order 
to reduce the amount of protein synthesis that would occur 
during the uptake experiments. The cells were then kept at 
37°C for 30 min, without shaking, in order to exhaust any 
remaining shikimate or aromatic biosynthetic intermedi- 
ates. The OD550 was then 1.61-1.82 (0.62-0.75 mg dry 
mass/ml). A 0.1-ml volume of this suspension was added 
to 4.9 ml of pre-warmed supplemented Medium 56 (but 
without arginine) in a 25-ml conical flask, and the new 
suspension maintained at 37°C for 3 min without shaking. 
At zero time, [14C]shikimic acid was added to a final 
concentration of 1.52 ~M (16.7/zl of a ten-fold dilution in 
water of the stock solution described above) and the flask 
shaken at 37°C. At specified times, samples were handled 
in one of two ways, depending on whether total cell-asso- 
ciated radiolabel, or only radiolabel incorporated into tri- 
chloroacetic acid (TCA)-insoluble material, was being 
measured. Where the total cell-associated radiolabel was 
being measured, a preliminary 0.1-ml sample was taken 
shortly before the full sample time point, in order to 
measure mpirically the cpm per unit volume of the reac- 
tion mixture. Beckman Ready Value aqueous cintillation 
fluid (4 ml) was added to this sample and the mixture 
counted as described below. The remaining suspension in 
the flask was vacuum-filtered at the specified time through 
a 0.45-/xm pore size, type HA Millipore filter. The flask 
was rinsed with 20 ml of 'wash-buffer' held at 37°C (50 
mM Hepes/150 mM NaC1, that had been adjusted to pH 
7.5 using 10 M NaOH solution), and the rinse drawn 
through the same filter. The filter was then washed with 
two more 20-ml volumes of the same wash-buffer. Where 
TCA-insoluble radiolabel was being measured, samples 
were handled as follows. At the required time, 20 ml of 
ice-cold TCA solution (5%, w/v )  was mixed rapidly with 
the 5 ml contents of the flask. The mixture was kept 
ice-cold for 15 min. A 0.1-ml liquid sample was then taken 
and mixed with 4.0 ml of scintillation fluid for determining 
empirically the specific radioactivity of the reaction mix- 
ture. The remaining sample of 24.9 ml was vacuum-filtered 
as above. The flask was rinsed and the filter washed also 
as described above, but this time with 20-ml volumes of 
ice-cold 5% TCA. For both types of determination, filters 
were dried at room temperature, placed in scintillation 
minivials and 4 ml of scintillation fluid added. All samples 
were counted in a Beckman LS 3801 counter and the 
counts corrected for background before analysis. The 
TCA-soluble pool of radiolabel was calculated as the 
difference between the total cell-associated [lnC]shikimate 
and the TCA-insoluble fraction. 
For some of the flasks, a further addition was made 60 s 
after the addition of [14C]shikimic acid. This consisted of 
either a 50-/zl or a 100-/zl volume of a concentrated 
solution of unlabelled compound whose ability to elicit 
exchange-diffusion was being studied. The solutions were 
as follows (see Fig. 1): shikimic acid, I, 17.4 mg/ml  to a 
final concentration of 0.99 mM; II, 19.2 mg/ml  to a final 
concentration of 0.99 raM, compound IV, 9.6 mg/ml  to a 
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Fig. 2. Uptake of [ 14 C]shikimate into the TCA-soluble pool of E. coli, and its displacement by excess unlabelled shikimate or (6 S)-6-fluoroshikimate. ((D) 
Uptake of [ lac]shikimate at 1.5 /,~M; ( [] ) addition of unlabelled shikimate to 0.99 mM at 60 s (arrow); ( zx ) addition of (6S)-6-fluoroshikimate II to 0.99 
mM at 60 s. 
final concentration of 0.98 mM; the mixture of V, VI and 
VII, 9.4 mg/ml to final concentrations of 0.67, 0.24 and 
0.08 mM, respectively; and barium chorismate, 18 mg/ml 
to a final concentration of 0.98 mM. Apart from these 
additions, samples were handled, and the radioactivity 
counted as described above. 
1.4 
1.2 
10 
m-~ 1.0 
0 
~ ¢~ 0 .8  
"6-6 
o E ¢.~ ¢.. 
N E 
0.,  
I..- 
0.2 
0 
0 
0 
n 
0,0  I' I I I I I I I 
0 20 40 60 80 1 O0 120 140 
Time (s) 
14 Fig. 3. Uptake of [ C]shikimate into the TCA-soluble pool of E. coli, and the effects of adding excess unlabelled shikimate, a mixture of three shikimate 
analogues, or chorismate. (©) Uptake of [ J4 C]shikimate at 1.5/zM; ([])  addition of unlabelled shikimate to 0.99 mM at 60 s (arrow); (zx) addition of the 
mixture of V, VI and VII to 0.67, 0.24 and 0.08 raM, respectively, at 60 s; (~)  addition of chorismate to 0.98 mM at 60 s. 
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The uptake of [~4C]shikimate into the TCA soluble pool 
of E. coli AB1360-7 was about three times more rapid 
than uptake into the parent strain, AB 1360; and the size of 
the cell-associated TCA-soluble pool was larger by a 
factor of 4 (data not shown). This increased pool size 
allowed us to perform the desired exchange-diffusion 
experiments [5]. 
The addition of a 650-fold excess (0.99 mM) of unla- 
belled shikimic acid I or of (6S)-6-fluoroshikimic a id I I  
caused kinetically-identical outflows of the pool of TCA- 
soluble 14C (Fig. 2). A mixture of three other shikimic acid 
analogues: 2-methylshikimic acid V, 1,2-/3-methylene- 
shikimic acid VI and 1,2-a-methylene-shikimic acid VII, 
at a combined final concentration of 0.98 mM, but in the 
ratio 68:24:8, respectively, also elicited an outflow with 
identical kinetics to that caused by shikimic acid (Fig. 3). 
One further shikimic acid analogue was tested, (6R)-6-flu- 
oro-4-epihydroxyshikimic acid IV. When it was added at a 
final concentration of 0.98 mM, it similarly caused an 
outflow of TCA-soluble radiolabel indistinguishable from 
that caused by shikimic acid itself (data not shown). 
Chorismate at a final concentration of ca. 1 mM did not 
cause the same outflow of radiolabelled shikimate (Fig. 3). 
The addition of either carbonyl cyanide m-chlorophenylhy- 
drazone (CCCP) at a final concentration of 20 /zM, or a 
mixture of cyanide and azide at a final concentration of 5 
mM of each, caused uptake to halt, but there was no 
outflow of radiolabel similar to that displayed in Figs. 2 
and 3 (data not shown). The addition of toluene at a final 
concentration of 2% (w/v)  caused a complete loss of the 
radiolabelled TCA-soluble intracellular pool of shikimate 
within 5 s (data not shown). 
The energetics of shikimate transport have not been 
studied previously. One reason why outflow was not ob- 
served when the uncoupler or respiration inhibitors were 
added might be that the transport system is kinetically 
'gated' and can only operate in the presence of a trans-cy- 
toplasmic-membrane protonmotive force or difference in 
electric potential. Tobramycin transport in E. coli, for 
example, only operates in the presence of a transmembrane 
electric potential of greater magnitude than about -120  
mV [7], which could account for some previously-unex- 
plained observations on the kinetics and energetics of 
aminoglycoside transport in general [8,9]. 
The hypothesis tested in the experiments reported here, 
namely that (6S)-6-fluoroshikimate I I  is a substrate for the 
shikimate transport system of E. coli, has been shown to 
be correct. This confirms that the variants that were resis- 
tant to (6S)-6-fluoroshikimate, and which also failed to 
take up shikimate [3], were resistant due to a lack of 
transport of the antibacterial compound into the cytoplasm. 
The shikimate transport system appeared to have a 
fairly broad specificity. Compound IV (Fig. 1), was also a 
substrate of the shikimate transporter indistinguishable from 
shikimate itself. The mixture of V, VI and VII  behaved 
indistinguishably from shikimate (Fig. 3); but we cannot 
conclude whether these three compounds were recognised 
equally by the shikimate transport system, because only 
the mixture was available to us. Lastly, we infer that the 
transport system can accept one further analogue as a 
substrate, (6R)-6-fluoroshikimate III, even though we did 
not have enough compound to perform exchange-diffu- 
sion experiments. The rationale for this inference is as 
follows. We have previously reported that in liquid Davis 
and Mingioli medium, using a low number of cells for the 
inoculum, E. coli K-12 was susceptible to both (6S)-6-flu- 
oroshikimate (IC50, 0.031 /~g/ml) and (6R)-6-fluoro- 
shikimate (IC50, 8.0 /xg/ml) [3]. The single-step, sponta- 
neous (6 S)-6-fluoroshikimate-resistant v riant derived from 
this strain of E. coli K-12, 'variant 20' (IC50 of (6S)-6- 
fluoroshikimate, 512 /xg/ml), was resistant due to lack of 
shikimate transport activity (see [3] for details). In the 
same susceptibility-test experiment, the IC50 of (6R)-6- 
fluoroshikimate for variant 20 was also 512 /xg/ml [3]. In 
other words, the absence of shikimate transport activity in 
variant 20 conferred on the strain resistance to both (6S)- 
6-fluoroshikimate and (6R)-6-fluoroshikimate. From this 
we conclude that the latter molecule must also be a 
substrate of the transport system. 
From the results obtained with shikimate analogues II, 
IV, V, VI and VII  (three of these being added as an 
unresolved mixture, Fig. 3), and deducing that (6R)-6-flu- 
oroshikimate I I I  is a substrate, the transport system ap- 
pears to tolerate a variety of structural features at positions 
1, 2, 4 and 6 of the shikimate molecule. The most surpris- 
ing of these is perhaps the acceptance of the epimeric 
hydroxyl at C-4 in IV. 
One more experiment is relevant o this observation. 
We determined the susceptibility of E. coli K-12 to IV at 
the same time as determining its susceptibility to I I  and 
III. The 2-ml agar-incorporation method [3] yielded MICs 
(minimum inhibitory concentrations) of II, I I I  and IV of 
0.125, 64 and > 1024 /zg/ml, respectively. Incidentally, 
the higher MICs of I I  and I I I  than those reported previ- 
ously [3] were due to the different method used: i.e. 
agar-solidified medium with a higher inoculum cell-den- 
sity. Thus IV was not antibacterial despite being a sub- 
strate for the shikimate transporter, and predictedly enter- 
ing the bacterial cytoplasm. We suggest that this is because 
IV, or one of its metabolites, was not a substrate of one of 
the enzymes further along the shikimate pathway; for 
example, shikimate kinase or EPSP (enolpyruvylshikimate- 
3-phosphate) synthase. This would be consistent with the 
idea that the orientation of the hydroxyl at C-4 in several 
intermediates of the pathway is important in substrate 
binding [10,11]; and that this orientation should be the 
same as that in shikimate itself for the 6-fluoro derivatives 
to be recognised as good substrates by the later enzymes of 
the pathway. 
As a practical consequence of the findings that a variety 
of shikimate analogues are accepted as transport substrates, 
one might attempt o exploit the broad specificity of the 
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shikimate transport system to smuggle other toxic shiki- 
mate analogues into bacterial cells as a means of designing 
antibacterial agents. However, because the system also 
appears to be lost at high frequency [3]; if analogues of 
shikimate are to be successful antibacterial agents, it will 
be necessary to introduce them into the bacterial cytoplasm 
via one or several other transport systems in addition to 
that which mediates the uptake of shikimate itself (e.g. see 
[12]). 
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